Clinical Trials Logo

Clinical Trial Summary

The aim of the trial is to assess the safety and efficacy of the orally-administered, selective complement C5a receptor inhibitor CCX168 (avacopan) in inducing and sustaining remission in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).


Clinical Trial Description

Complement 5a and its receptor C5aR (CD88) are involved in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

This is a randomized, double-blind, active-controlled Phase 3 study to evaluate the safety and efficacy of the orally-administered, selective C5aR inhibitor CCX168 (avacopan) in inducing and sustaining remission in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treated concomitantly with Rituximab or Cyclophosphamide/Azathioprine. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02994927
Study type Interventional
Source ChemoCentryx
Contact
Status Completed
Phase Phase 3
Start date March 15, 2017
Completion date November 1, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT02257866 - Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Completed NCT02463539 - Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis N/A
Completed NCT02222155 - Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis Phase 2
Terminated NCT00482066 - Abatacept in ANCA Associated Vasculitis Phase 2
Not yet recruiting NCT02126098 - Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis N/A
Recruiting NCT02463578 - Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis N/A
Completed NCT02954705 - MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS
Recruiting NCT04280601 - PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis N/A
Recruiting NCT02108860 - Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) Phase 3